180 related articles for article (PubMed ID: 7104969)
1. Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C).
Breithaupt H; Pralle H; Eckhardt T; von Hattingberg M; Schick J; Löffler H
Cancer; 1982 Oct; 50(7):1248-57. PubMed ID: 7104969
[TBL] [Abstract][Full Text] [Related]
2. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.
Capizzi RL; Yang JL; Cheng E; Bjornsson T; Sahasrabudhe D; Tan RS; Cheng YC
J Clin Oncol; 1983 Dec; 1(12):763-71. PubMed ID: 6668493
[TBL] [Abstract][Full Text] [Related]
3. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias.
Periclou AP; Avramis VI
Cancer Chemother Pharmacol; 1996; 39(1-2):42-50. PubMed ID: 8995498
[TBL] [Abstract][Full Text] [Related]
4. Does the metabolite uracil arabinoside inhibit cytosine arabinoside (Ara-C) penetration into the cerebrospinal fluid during high-dose Ara-C therapy?
van Prooijen HC; Muus P; Roelofs JM; Punt K
Scand J Haematol; 1986 Jan; 36(1):123-6. PubMed ID: 3456631
[TBL] [Abstract][Full Text] [Related]
5. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
[TBL] [Abstract][Full Text] [Related]
6. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside.
DeAngelis LM; Kreis W; Chan K; Dantis E; Akerman S
Cancer Chemother Pharmacol; 1992; 29(3):173-7. PubMed ID: 1733548
[TBL] [Abstract][Full Text] [Related]
8. Cytosine arabinoside cerebrospinal fluid kinetics.
Zimm S; Collins JM; Miser J; Chatterji D; Poplack DG
Clin Pharmacol Ther; 1984 Jun; 35(6):826-30. PubMed ID: 6587957
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
10. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.
Slevin ML; Piall EM; Aherne GW; Harvey VJ; Johnston A; Lister TA
J Clin Oncol; 1983 Sep; 1(9):546-51. PubMed ID: 6583325
[TBL] [Abstract][Full Text] [Related]
11. [Results of therapy with high-dose cytosine arabinoside].
Pralle H; Breithaupt H
Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia.
Ochs J; Sinkule JA; Danks MK; Look AT; Bowman WP; Rivera G
J Clin Oncol; 1984 Oct; 2(10):1092-7. PubMed ID: 6593435
[TBL] [Abstract][Full Text] [Related]
13. The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse.
van Prooijen HC; Dekker AW; Punt K
Br J Haematol; 1984 Jun; 57(2):291-9. PubMed ID: 6733049
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
Grant S; Baker M; Bhalla K
Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091
[TBL] [Abstract][Full Text] [Related]
15. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
16. ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.
Liliemark JO; Gahrton G; Paul CY; Peterson CO
Semin Oncol; 1987 Jun; 14(2 Suppl 1):167-71. PubMed ID: 3589691
[TBL] [Abstract][Full Text] [Related]
17. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
Damon LE; Plunkett W; Linker CA
Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia.
Stone RM; Spriggs DR; Dhawan RK; Arthur KA; Mayer RJ; Kufe DW
Leukemia; 1990 Dec; 4(12):843-7. PubMed ID: 2243507
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
[TBL] [Abstract][Full Text] [Related]
20. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.
Scott-Moncrieff JC; Chan TC; Samuels ML; Cook JR; Coppoc GL; DeNicola DB; Richardson RC
Cancer Chemother Pharmacol; 1991; 29(1):13-8. PubMed ID: 1742843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
